Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,160 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04365751Recruiting
Microwave ablation versus surgery for liver cancer
This trial compares two ways to treat hepatocellular carcinoma (a type of liver cancer): microwave ablation and laparoscopic hepatectomy (keyhole liver surgery). It may help find which option works better for tumor control and recovery in people with limited, non-spread cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04376866RecruitingPhase 3
Immunotherapy for repeat nasopharyngeal cancer after it returns
This trial studies toripalimab (an immunotherapy that helps your immune system attack cancer) for nasopharyngeal cancer that has come back locally. It may help shrink or control the returning tumor and improve outcomes for people who meet the safety and lab requirements.
Nanning, GuangxiAges 18–65 - NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
Anchorage, AlaskaAges 18 years+ - NCT04425265Recruiting
Low-temperature plasma treatment vs high-frequency cautery for recurring cancer
This trial compares two ways of surgically treating localized, recurrent nasopharyngeal cancer: a low-temperature plasma radiofrequency method versus a standard high-frequency cautery method. You might be eligible if your recurrence is limited and can be surgically removed, and you are within the allowed health and age ranges.
Guangzhou, GuangdongAges 18–70 - NCT04436965RecruitingPhase 3
Standard nutrition support for malnourished nasopharyngeal cancer patients
This Phase 3 study tests whether giving a standard nutrition plan can improve nutritional status and outcomes in people with locally advanced nasopharyngeal cancer who are malnourished. It mainly checks whether nutrition support helps you tolerate treatment and do better over time.
Guangzhou, GuangdongAges 18–65 - NCT04437329RecruitingPhase 3
Nedaplatin vs cisplatin for nasopharyngeal cancer
This trial compares two chemotherapy drugs—nedaplatin versus cisplatin—in people newly diagnosed with a specific type of nasopharyngeal cancer. The goal is to see which drug works better and/or has a safer side-effect profile when given as part of standard treatment.
Guangzhou, GuangdongAges 18–65 - NCT04444869RecruitingPhase 2
Lower-dose radiation with chemotherapy for low-risk HPV throat cancer
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
Columbia, MissouriAges 18 years+ - NCT04448522RecruitingPhase 3
Lower-dose radiotherapy for EBV-responsive nasopharyngeal cancer
This Phase 3 study tests whether giving a reduced amount of radiotherapy can work as well as the standard dose for certain people with stage II–III nasopharyngeal cancer who respond well after initial chemotherapy. It’s designed for patients whose cancer markers improve after 3 chemotherapy cycles, to potentially reduce treatment side effects while keeping cancer control.
Guangzhou, GuangdongAges 18–70 - NCT04453813RecruitingPhase 3
Immunotherapy with chemoradiation for recurring nasopharyngeal cancer
This phase 3 trial tests whether adding toripalimab (an immunotherapy medicine) to standard chemo-radiation works better for treating nasopharyngeal cancer that has come back and cannot be removed by surgery. It aims to improve control of the cancer after it returns.
Guangzhou, GuangdongAges 18–70 - NCT04481256Recruiting
Immunotherapy with chemoradiation for esophageal cancer
This trial tests adding medicines that block TGF-beta and PD-L1 to standard chemoradiation for esophageal squamous cell cancer that can’t be removed with surgery. It aims to improve control of the cancer where it sits, while keeping treatment safe.
AmsterdamAges 18 years+ - NCT04499833Recruiting
Test an AI score to guide liver transplant decisions
This study looks at a prediction tool that estimates outcomes for people with liver cancer and cirrhosis, to help decide whether a liver transplant is a good option. It may help doctors choose the right timing and patients who could benefit most from transplantation.
LisbonAges 18–70 - NCT04510597RecruitingPhase 3
Immunotherapy plus surgery versus immunotherapy alone for kidney cancer
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
Birmingham, AlabamaAges 18 years+ - NCT04512833Recruiting
CyberKnife radiation for small liver cancer with cirrhosis
This trial tests CyberKnife stereotactic body radiation therapy—targeted high-precision radiation—for small hepatocellular carcinoma (liver cancer) in people with decompensated cirrhosis. It may help if other liver cancer treatments aren’t possible, but it has strict safety rules about tumor spread and nearby organs.
BeijingAges 30–80 - NCT04519905Recruiting
Testing two ways of radiation in older esophagus cancer patients
This study compares a planned radiation approach given at the same time as other treatment for older adults with esophageal squamous cell carcinoma. It may help find a safer and more effective radiation schedule for people who are fit enough for treatment.
Nanjing, JiangsuAges 76 years+ - NCT04528420Recruiting
Early treatment plan for head and neck skin cancer
This study tests an optimized plan for treating squamous cell cancer in the head and neck area using curative treatment that includes chemotherapy with cisplatin plus radiation after surgery. It may help doctors improve early management and outcomes for people eligible for this standard approach.
AmiensAges 18–75 - NCT04529044RecruitingPhase 2
177Lu-DOTATATE for advanced breast cancer with targeted receptors
This Phase 2 trial tests whether 177Lu-DOTATATE can slow or shrink stage IV or recurrent breast cancer. It targets tumor “receptors” found on scans, using a radioactive medicine that delivers radiation directly to cancer cells.
Portland, OregonAges 18–100 - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Irvine, CaliforniaAges 12 years+ - NCT04587739RecruitingPhase 1
Radiation before surgery for a single liver tumor
This early feasibility study tests a radiation plan given before surgery for hepatocellular carcinoma (a type of liver cancer) to see if it’s safe and doable. It may help shrink or control the tumor before an operation that aims to fully remove it.
LilleAges 18–70 - NCT04595864RecruitingPhase 3
Chemotherapy into the liver before transplant for liver cancer
This trial tests whether giving chemotherapy directly into the liver blood supply before a liver transplant can help people with liver cancer that is beyond standard transplant criteria. It may help lower cancer risk around the time of transplant while keeping people healthy enough to receive the transplant.
Nanjing, JiangsuAges 18–75 - NCT04617756RecruitingPhase 2
Durvalumab plus chemo before surgery for high-risk upper urinary tract cancer
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
Paris, Paris Cx 20Ages 18 years+ - NCT04666961RecruitingPhase 2
Hormone therapy before surgery for extensive DCIS
This Phase 2 study tests whether taking hormone medicine before surgery can change the surgical plan and outcomes for people with extensive ductal carcinoma in situ (DCIS). It is for estrogen-receptor positive DCIS and aims to see how this “neoadjuvant” approach affects treatment decisions.
AngersAges 40 years+ - NCT04678362RecruitingPhase 2
Maintenance treatment with talazoparib plus immunotherapy for bladder cancer
This trial tests whether continuing two medicines after your initial platinum chemotherapy can help keep your urothelial (bladder/urine tract) cancer from coming back or worsening. It is for people whose cancer shrank or stayed stable after chemotherapy and who cannot be cured with surgery or radiation.
AngersAges 18 years+ - NCT04724018RecruitingPhase 1/Phase 2
Enfortumab and sacituzumab for metastatic bladder cancer
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT04749108RecruitingPhase 2/Phase 3
Tailored treatment for locally advanced rectal cancer after FOLFIRINOX
This trial studies a more customized treatment plan for people with locally advanced rectal (bowel) cancer after they receive FOLFIRINOX chemotherapy. It aims to reduce tumor spread risk and improve outcomes by tailoring the next steps based on scan details and your health status.
Marseille, Bouches Du RhôneAges 18 years+
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,160 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.